Protalix BioTherapeutics, Inc. Common Stock (PLX) — 分析摘要
Protalix BioTherapeutics, Inc. Common Stock（PLX）的市值为192.57百万美元，最近一年的营收同比增长了-1.2%。净利润率为-12.5%。当前市盈率为12.6倍。
核心要点
- 营收同比变化-1.2%
- 净利润率-12.5%
- 市盈率12.6倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，PLX的营收增长为-1.2%，市盈率为12.6倍。
Protalix BioTherapeutics, Inc. Common Stock (PLX)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
226
总部
HACKENSACK, NJ
Exchange
XASE
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。